semaglutide being taken off the market An Ongoing Crisis: Shortage Raises Dual Concerns for Obesity and Diabetes Treatment The black market for weight-loss

A landmark study found that approximately 70% of patients who discontinued semaglutide regained weight over the following year, though individual outcomes varied considerably

Recent research has revealed that GLP-1 peptides, specifically semaglutide and tirzepatide, show remarkable potential in reducing alcohol consumption among individuals with obesity

For those not on GLP-1 medications but looking to support appetite and craving control through GLP-1 receptor activation, check out the GLP-ONE Activator Bundle.*

Endocrinology 149 , 574579 (2008)

The dose matters less than you might thinkeven microdose protocols can trigger initial nausea in sensitive individuals

But semaglutide is not just any peptide